Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.
Source updated2026-09-21Last update listed in the registry record
Version history
Changes to this trial
Last 12 months
Pro unlocks the full available history and CSV export. View Pro features
· 1 field changed
Primary outcomes · main study measures
Text edit · unverified significance
− Previous value
measure: Evaluation of efficacy of AL001 as measured by the CDR® plus NACC FTLD-SB
+ Updated value
measure: Part 1 Double Blind - Evaluation of Efficacy of AL001 Compared With Placebo as Measured by the CDR® Plus NACC FTLD-SB in Symptomatic Patients; measure: Part 1 Double Blind (Co-Primary US Endpoint) - Evaluation of the Treatment Effect of AL001 Compared With Placebo as Measured by Pharmacodynamic and Disease Pathology Biomarkers in Symptomatic Patients; measure: Part 2 OLE - To Assess the Long-term Safety and Tolerability of AL001 in Participants Who Have Completed Part 1 of the Study
The saved outcome text may be shortened. Check the source for full wording.
Trial